KLH to fight the disease of forgetfulness: Researchers closing in on a vaccine

KLH to fight the disease of forgetfulness: Researchers closing in on a vaccine

The memory loss disorder eponymously called Alzheimer's burdens around 44 million people worldwide, according to the statistics reported by “Alzheimer’s News Today”. The prevalence of this neurodegenerative disease is as pathologically progressive as is its clinical course. Absent any cure or any way to stop or slow progression, the only options are symptomatic treatments and coping strategies for patients and their loved ones. Therefore, many committed researchers have long set their sights on developing a vaccine to ward off the disease’s neurodegenerative mental decline.

Working with Nobel Laureates, the dedicated scientists at Axon Neuroscience SE had discovered that neurofibrillary tangles of tau proteins are associated with the neuronal disconnect of brain synapses. So they started targeting tau, a protein omnipresent in all cells. Tau proteins are vital to brain health and normal functioning. But as usually happens with too much of a good thing, when tau proteins buildup in the brain, they cause the damage that makes neurons lose their interconnectivity. This makes Alzheimer sufferers confused and forgetful. But now, promise is on the horizon. The first-in-class Alzheimer vaccine being developed by Axon Neuroscience, known as AADvac1, is an Axon peptide 108 conjugated to keyhole limpet hemocyanin (KLH). As large-molecule carrier substance, KLH gets the body’s immune system to show a stronger reaction to the vaccine. biosyn is supplying KLH in the form of its research-grade, cGMP-manufactured VACMUNE (immunocyanin) and is indeed optimistic. The initial results of the phase II placebo-controlled ADAMANT clinical trial have compelled Axon Neuroscience to move to the next step: plans for clinical development based on their positive data. Here, biosyn’s blue-blooded sea snail is again carrying its weight in the fight against yet another severe disease.

To read the Axon Neuroscience press release, go to:

Axon announces positive results from Phase II ADAMANT trial for AADvac1 in Alzheimer’s Disease

  1. immunotherapy
  2. vaccine development
  3. immunosenescence